Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies

Pain and Therapy

Volumn 4, Issue 2, 2015, Pages 169-178

  Del Giorno, Rosaria ^a   Skaper, Stephen ^b   Paladini, Antonella ^c   Varrassi, Giustino ^c,d   Coaccioli, Stefano ^a,d  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d European League against Pain   (Switzerland)

Author keywords

Chronic pain; Duloxetine; Fibromyalgia; Multimodal therapy; Pain; Palmitoylethanolamide; Pregabalin

Indexed keywords

DULOXETINE; PALMIDROL; PREGABALIN;

ADULT; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ASSESSMENT; DATA PROCESSING; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PAIN; PAIN INTENSITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; VISUAL ANALOG SCALE;

EID: 84984802918     PISSN: 21938237     EISSN: 2193651X     Source Type: Journal    
DOI: 10.1007/s40122-015-0038-6     Document Type: Article

References (42)

1. Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep. 2013;17(8):356.
2. Todesco S, Gambari PF, Punzi L. Malattie reumatiche. IV ed. Milano: McGraw-Hill; 2007.
3. Kim J, Loggia ML, Cahalan CM, et al. The somatosensory link in fibromyalgia: functional connectivity of the primary somatosensory cortex is altered by sustained pain and is associated with clinical/autonomic dysfunction. Arthritis Rheumatol Hoboken NJ. 2015;67(5):1395–405.
4. Napadow V, Harris RE. What has functional connectivity and chemical neuroimaging in fibromyalgia taught us about the mechanisms and management of “centralized” pain? Arthritis Res Ther. 2014;16(5):425.
5. Romero-Sandoval EA, Sweitzer S. Nonneuronal central mechanisms of pain: glia and immune response. Prog Mol Biol Transl Sci. 2015;131:325–58.
6. Staud R. Cytokine and immune system abnormalities in fibromyalgia and other central sensitivity syndromes. Curr Rheumatol Rev. 2015;11(2):109–15.
7. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160–72.
8. Wolfe F, Clauw DJ, Fitzcharles M-A, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38(6):1113–22.
9. Dombernowsky T, Dreyer L, Bartels EM, Danneskiold-Samsøe B. Muscular strength in patients with fibromyalgia. A literature review. Ugeskr Laeger. 2008;170(4):217–24.
10. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005;75:6–21.
11. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547–55.
12. Sommer C, Häuser W, Gerhold K, et al. Etiology and pathophysiology of fibromyalgia syndrome and chronic widespread pain. Schmerz Berl Ger. 2008;22(3):267–82.
13. Tavel ME. Somatic symptom disorders without known physical causes: one disease with many names? Am J Med. 2015;. doi:10.1016/j.amjmed.2015.04.041.
14. Coaccioli S, Varrassi G, Sabatini C, Marinangeli F, Giuliani M, Puxeddu A. Fibromyalgia: nosography and therapeutic perspectives. Pain Pract Off J World Inst Pain. 2008;8(3):190–201.
15. Dell’Osso L, Arnold L, Baroni S, et al. The inflammatory hypothesis of mood spectrum broadened to fibromyalgia and chronic fatigue syndrome. Clin Exp Rheumatol. 2014;33(1 Suppl 88):S109–16.
16. Rodriguez-Pintó I, Agmon-Levin N, Howard A, Shoenfeld Y. Fibromyalgia and cytokines. Immunol Lett. 2014;161(2):200–3.
17. Staud R, Rodriguez ME. Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract Rheumatol. 2006;2(2):90–8.
18. Dedhia JD, Bone ME. Pain and fibromyalgia. Contin Educ Anaesth Crit Care Pain. 2009;9(5):162–6 (1).
19. Hawley DJ, Wolfe F. Pain, disability, and pain/disability relationships in seven rheumatic disorders: a study of 1522 patients. J Rheumatol. 1991;18(10):1552–7.
20. Bergman S. Psychosocial aspects of chronic widespread pain and fibromyalgia. Disabil Rehabil. 2005;27(12):675–83.
21. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol. 2003;17(4):685–701.
22. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;3:CD007938.
23. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia–responder analysis from individual patient data. BMC Musculoskelet Disord. 2010;11:150.
24. Häuser W, Bernardy K, Uçeyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA. 2009;301(2):198–209.
25. Arnold LM. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med Malden Mass. 2007;8(Suppl 2):S63–74.
26. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432–44.
27. Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain Off J Am Pain Soc. 2010;11(6):505–21.
28. Kuehl FA, Jacob TA, Ganley OH, Ormond RE, Meisinger MAP. The identification of N-(2-Hydroxyethyl)-Palmitamide as a naturally occurring anti-inflammatory agent. J Am Chem Soc. 1957;79(20):5577–8.
29. Skaper SD, Facci L, Barbierato M, Zusso M, Bruschetta G, Impellizzeri D, et al. N-Palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution. Mol Neurobiol. 2015. doi:10.1007/s12035-015-9253-8.
30. Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014;22(2):79–94.
31. Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions. 1993;39 Spec No:C145–7.
32. Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med Malden Mass. 2012;13(9):1121–30.
33. Luongo L, Maione S, Di Marzo V. Endocannabinoids and neuropathic pain: focus on neuron-glia and endocannabinoid-neurotrophin interactions. Eur J Neurosci. 2014;39(3):401–8.
34. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science. 2013;339(6116):166–72.
35. Petrosino S, Iuvone T, Di Marzo V. N-Palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities. Biochimie. 2010;92(6):724–7.
36. Impellizzeri D, Bruschetta G, Cordaro M, et al. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation. 2014;11:136.
37. Freitag CM, Miller RJ. Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines? Front Cell Neurosci. 2014;8:238.
38. Miller RJ, Jung H, Bhangoo SK, White FA. Cytokine and chemokine regulation of sensory neuron function. Handb Exp Pharmacol. 2009;194:417–49.
39. Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012;26(2):99–104.
40. Truini A, Biasiotta A, Di Stefano G, et al. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord: Drug Targets. 2011;10(8):916–20.
41. Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623.
42. ®) en el dolor neuropático crónico por lumbociatalgia de tipo compresivo:estudio clinico multícéntrico. Dolor. 2010;25:35–42.